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From the processed data we concluded that PLGA nanoparticles are optimal
carriers for a large number of active substances providing higher solubility,
greater stability and improved bioavailability.
The therapeutic potential of a number of active substances can not be realized in clinical practice because of the unfavorable physical-
chemical properties, the variable pharmacokinetics and the range of side-effects that cause low bioavailability and unsatisfactory
therapeutic concentration in the target tissue. A possible approach to overcome these limitations is the encapsulation of.the active
substances in nanoparticles. The most commonly investigated and characterized nanosystems are the formulations based on PLGA as a
biocompatible, biodegradable and approved polymer by the FDA.
For the purpose, we did a detailed overview of data from
clinical studies of various formulations of PLGA, process
of preparation and characterization of their structure,
influence of various parameters on stability are processed
and the patented formulations placed on the market are
listed.
RESULTS AND DISCUSSION
-We obtained the data by searching a relevant scientific-professional
literature, we pointed out the advantages and disadvantages of the
nanoparticles and discussed the results of clinical studies of various
active substances incorporated in PLGA nanoparticles. From the
processed data we concluded that PLGA nanoparticles are optimal
carriers for a large number of active substances providing higher
solubility, greater stability and improved bioavailability.
Figure 1. Structure of PLGA
